Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
February 14, 2025 16:15 ET
|
Edesa Biotech, Inc.
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
February 13, 2025 07:00 ET
|
Edesa Biotech, Inc.
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s CXCL10 antibody program through the end of...
Edesa Biotech Reports Fiscal Year 2024 Results
December 13, 2024 16:30 ET
|
Edesa Biotech, Inc.
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Edesa Biotech’s Founder Makes Strategic Investment in the Company
October 31, 2024 08:15 ET
|
Edesa Biotech, Inc.
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
Edesa Biotech Announces Upcoming Conference Schedule
October 21, 2024 08:15 ET
|
Edesa Biotech, Inc.
Edesa Biotech Announces Upcoming Conference Schedule
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
August 09, 2024 16:20 ET
|
Edesa Biotech, Inc.
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...